News
Scientists Visualize How Therapeutic Antibody Binds to SARS-CoV-2 Variants
Last year, scientists studied the blood of 14 COVID-19 survivors to find the most potent antibodies against the SARS-CoV-2 virus. One of the leading molecules, an antibody dubbed J08, is now in clinical trials in Italy. Now, the same group has visualized exactly how J08 binds to different SARS-CoV-2 variants in different conformations, explaining what makes the monoclonal antibody so potent.